Cleveland Diagnostics

We’re pleased to share that an independent longitudinal study of our IsoPSA test has been published in Urology, further validating IsoPSA’s accuracy and predictive value for prostate cancer detection and risk assessment. Key Findings: - Low-risk patients (IsoPSA Index ≤6) maintained a low risk of clinically significant prostate cancer (csPCa) for up to 30 months, which suggests biopsy can be deferred or intervals between biopsies can be extended. - High-risk patients (IsoPSA Index >6) had consistently higher csPCa risk across all intervals evaluated, with nearly 50% developing csPCa within 30 months, highlighting the need for closer monitoring. This study underscores our commitment to precision oncology. We’re proud to provide a test that helps low-risk patients avoid unnecessary interventions while ensuring high-risk patients are identified who would benefit from closer monitoring. Learn more here: https://hubs.la/Q03jwH5r0 #IsoPSA #ProstateCancer #Urology #PrecisionMedicine

In celebration of Lab Week, we’re taking a moment to recognize the invaluable contributions of our team at Cleveland Diagnostics. Their dedication to ensuring accurate diagnoses and improving patient care, especially in the area of prostate cancer testing, is at the heart of everything we do. To laboratory professionals everywhere, including our own exceptional team, thank you for your unwavering commitment and expertise. Your work continues to drive progress in prostate cancer detection and beyond. #MedLabWeek #HealthcareHeroes #LabWeek

In a new feature from Today's Clinical Lab, our CEO & co-founder, Arnon Chait, PhD, MBA, discussed the transformative potential of innovative diagnostic tests in early cancer detection. Cancer screening is a critical public health measure, but getting a timely diagnosis can be an uphill battle for patients. Dr. Chait shared that when implemented, tests like IsoPSA can help streamline the diagnostic process for patients while avoiding overdiagnosis and unnecessary treatment in patients with nonactive or benign conditions. By providing results closely linked to the biological processes of cancer, advanced early detection diagnostics can enhance decision-making, conserve healthcare resources, and improve the prioritization of high-risk patients. For more insights, read the full article here: https://hubs.la/Q03hGlFF0 #prostatecancer #cancerdetection #IsoPSA #cancertesting

All men are at risk for prostate cancer, but factors like age, family history, and ethnicity can increase that risk. Recognizing these factors—along with the importance of early detection and accurate testing—is crucial for timely diagnosis and better health outcomes. Learn more with insights from ZERO Prostate Cancer: https://hubs.la/Q03fRy9X0

IsoPSA offers a precise method for assessing prostate cancer risk by analyzing cancer-related changes to PSA proteins—because the proof is in the protein structure. This enables clinicians to identify patients who may benefit from a prostate biopsy, facilitating more effective patient counseling. Discover how IsoPSA can make a difference in prostate cancer care at https://hubs.la/Q03fRCM-0.

When it comes to prostate cancer testing, accuracy is crucial for early detection and timely treatment. IsoPSA goes beyond standard PSA tests by identifying structural changes in PSA proteins that may be linked to cancer and, in doing, so more accurately assesses risk of clinically significant prostate cancer. This approach enables clinicians to make more informed biopsy decisions, helping to ensure patients receive the right care at the right time. Learn more: https://hubs.la/Q03fRwDp0

#ICYMI we recently announced that our IsoPSA test is officially available nationwide through Quest Diagnostics! This expanded access is a major development in providing patients and physicians with a more accurate approach to assessing #prostatecancer risk. Learn more: https://hubs.ly/Q03fBBcn0

#ICYMI our VP of R&D, Erez Podoly, PhD, recently shared his perspective on what 2025 holds for the #biopharma industry, emphasizing the ongoing shift toward precision medicine. As we advance more accurate methods for assessing the risk of clinically significant #prostatecancer, we're proud to be part of the movement that empowers clinicians to deliver more precise, patient-centered care. By improving diagnostic test development and delivery, we’re contributing to a future of personalized disease management and care, ensuring better outcomes for patients. Read the full article here: https://hubs.la/Q03bx6320 Citeline

IsoPSA clarifies #prostatecancer risk by assessing structural differences in PSA proteins that are expressed by cancer. This approach is a more specific measure of #prostatecancer, helping to identify men who would benefit from a biopsy and those who would not. Learn more about IsoPSA: https://hubs.la/Q03bxnCH0

For the latest news, updates, and insights specific to IsoPSA and #prostatecancer testing, be sure to follow our dedicated IsoPSA LinkedIn page at https://hubs.la/Q03bxqnR0.